These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 26260669)

  • 1. HTLV-1-associated adult T cell leukemia is highly susceptible to Navitoclax due to enhanced Bax expression.
    Witzens-Harig M; Giaisi M; Köhler R; Krammer PH; Li-Weber M
    Int J Cancer; 2016 Jan; 138(2):507-14. PubMed ID: 26260669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting CDK9 by wogonin and related natural flavones potentiates the anti-cancer efficacy of the Bcl-2 family inhibitor ABT-263.
    Polier G; Giaisi M; Köhler R; Müller WW; Lutz C; Buss EC; Krammer PH; Li-Weber M
    Int J Cancer; 2015 Feb; 136(3):688-98. PubMed ID: 24895203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia.
    Zhang M; Mathews Griner LA; Ju W; Duveau DY; Guha R; Petrus MN; Wen B; Maeda M; Shinn P; Ferrer M; Conlon KD; Bamford RN; O'Shea JJ; Thomas CJ; Waldmann TA
    Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12480-5. PubMed ID: 26396258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: in vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737.
    Ishitsuka K; Kunami N; Katsuya H; Nogami R; Ishikawa C; Yotsumoto F; Tanji H; Mori N; Takeshita M; Miyamoto S; Tamura K
    Cancer Lett; 2012 Apr; 317(2):218-25. PubMed ID: 22138435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia/lymphoma.
    Kunami N; Katsuya H; Nogami R; Ishitsuka K; Tamura K
    Anticancer Res; 2014 Oct; 34(10):5287-94. PubMed ID: 25275021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models.
    Tan N; Malek M; Zha J; Yue P; Kassees R; Berry L; Fairbrother WJ; Sampath D; Belmont LD
    Clin Cancer Res; 2011 Mar; 17(6):1394-404. PubMed ID: 21220478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspirin overcomes Navitoclax-resistance in hepatocellular carcinoma cells through suppression of Mcl-1.
    Li G; Zhang S; Fang H; Yan B; Zhao Y; Feng L; Ma X; Ye X
    Biochem Biophys Res Commun; 2013 May; 434(4):809-14. PubMed ID: 23611778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection of mitochondrial perturbation by human T-lymphotropic virus type 1 tax through induction of Bcl-xL expression.
    Nakashima K; Kawakami A; Hida A; Yamasaki S; Nakamura H; Kamachi M; Miyashita T; Tanaka F; Izumi Y; Tamai M; Ida H; Furuyama M; Koji T; Nakamura T; Migita K; Origuchi T; Eguchi K
    J Lab Clin Med; 2003 Nov; 142(5):341-7. PubMed ID: 14647038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ascorbic acid induces apoptosis in adult T-cell leukemia.
    Harakeh S; Diab-Assaf M; Khalife JC; Abu-el-Ardat KA; Baydoun E; Niedzwiecki A; El-Sabban ME; Rath M
    Anticancer Res; 2007; 27(1A):289-98. PubMed ID: 17352246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).
    Phillips DC; Xiao Y; Lam LT; Litvinovich E; Roberts-Rapp L; Souers AJ; Leverson JD
    Blood Cancer J; 2015 Nov; 5(11):e368. PubMed ID: 26565405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.
    Wilson WH; O'Connor OA; Czuczman MS; LaCasce AS; Gerecitano JF; Leonard JP; Tulpule A; Dunleavy K; Xiong H; Chiu YL; Cui Y; Busman T; Elmore SW; Rosenberg SH; Krivoshik AP; Enschede SH; Humerickhouse RA
    Lancet Oncol; 2010 Dec; 11(12):1149-59. PubMed ID: 21094089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.
    Roberts AW; Seymour JF; Brown JR; Wierda WG; Kipps TJ; Khaw SL; Carney DA; He SZ; Huang DC; Xiong H; Cui Y; Busman TA; McKeegan EM; Krivoshik AP; Enschede SH; Humerickhouse R
    J Clin Oncol; 2012 Feb; 30(5):488-96. PubMed ID: 22184378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.
    Leverson JD; Phillips DC; Mitten MJ; Boghaert ER; Diaz D; Tahir SK; Belmont LD; Nimmer P; Xiao Y; Ma XM; Lowes KN; Kovar P; Chen J; Jin S; Smith M; Xue J; Zhang H; Oleksijew A; Magoc TJ; Vaidya KS; Albert DH; Tarrant JM; La N; Wang L; Tao ZF; Wendt MD; Sampath D; Rosenberg SH; Tse C; Huang DC; Fairbrother WJ; Elmore SW; Souers AJ
    Sci Transl Med; 2015 Mar; 7(279):279ra40. PubMed ID: 25787766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of survivin in HTLV-I-infected T-cell lines and primary ATL cells.
    Mori N; Yamada Y; Hata T; Ikeda S; Yamasaki Y; Tomonaga M; Yamamoto N
    Biochem Biophys Res Commun; 2001 Apr; 282(5):1110-3. PubMed ID: 11302729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of mammalian target of rapamycin signaling by everolimus induces senescence in adult T-cell leukemia/lymphoma and apoptosis in peripheral T-cell lymphomas.
    Darwiche N; Sinjab A; Abou-Lteif G; Chedid MB; Hermine O; Dbaibo G; Bazarbachi A
    Int J Cancer; 2011 Aug; 129(4):993-1004. PubMed ID: 21064094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of AID by human T-cell leukemia virus Tax oncoprotein and the possible role of its constitutive expression in ATL genesis.
    Ishikawa C; Nakachi S; Senba M; Sugai M; Mori N
    Carcinogenesis; 2011 Jan; 32(1):110-9. PubMed ID: 20974684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma.
    Ng SY; Davids MS
    Clin Adv Hematol Oncol; 2014 Apr; 12(4):224-9. PubMed ID: 25003352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adult T-cell leukemia-lymphoma.
    Tsukasaki K
    Hematology; 2012 Apr; 17 Suppl 1():S32-5. PubMed ID: 22507774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Celecoxib disrupts the canonical apoptotic network in HTLV-I cells through activation of Bax and inhibition of PKB/Akt.
    Sinha-Datta U; Taylor JM; Brown M; Nicot C
    Apoptosis; 2008 Jan; 13(1):33-40. PubMed ID: 17952603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human breast cancer cells display different sensitivities to ABT-263 based on the level of survivin.
    Lee EY; Gong EY; Shin JS; Moon JH; Shim HJ; Kim SM; Lee S; Jeong J; Gong JH; Kim MJ; Lee DH; Park YS; Shin J; Hong SW; Kim YS; Jin DH
    Toxicol In Vitro; 2018 Feb; 46():229-236. PubMed ID: 28947240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.